Form 4: ORIC CEO Sells Over $1M in Stock Under 10b5-1 Plan

Oric Pharmaceuticals' President and CEO, Jacob Chacko, sold 87,539 shares of common stock for over $1 million in two transactions.

Summary

• Jacob Chacko, President and CEO of Oric Pharmaceuticals, Inc. (ORIC), reported two sales of common stock.
• On September 30, 2025, Chacko sold 34,538 shares at a weighted average price of $12.0085 per share, totaling approximately $414,721.
• On October 1, 2025, an additional 53,001 shares were sold at a weighted average price of $12.0527 per share, totaling approximately $638,712.
• The total value of shares sold across both transactions is approximately $1,053,433.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Chacko on June 21, 2025.
• Following these transactions, Mr. Chacko beneficially owns 568,880 shares of common stock directly.
• Mr. Chacko also holds 178,667 restricted stock units (RSUs) and stock options to purchase 3,378,000 shares, which are not included in the reported beneficial ownership number for common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling by the CEO. While the sales were pre-planned under a 10b5-1 plan, which mitigates some concerns, large insider sales can still be interpreted by the market as a lack of confidence or a move to diversify personal holdings, potentially impacting investor sentiment.

Negatives

• Significant insider selling by the President and CEO, even if pre-planned, can sometimes be perceived negatively by investors.

Risks

• Investor perception of insider selling could potentially lead to negative sentiment towards the stock, despite the sales being pre-scheduled under a 10b5-1 plan.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider stock transactions and does not provide broader industry context. It reflects an individual executive's portfolio management rather than a company-wide strategic move or industry trend.

Stakeholder Impact

• Shareholders: May interpret the CEO's stock sales as a signal, potentially influencing their investment decisions. The pre-planned nature (10b5-1) provides transparency but does not eliminate the perception of an insider reducing exposure.

Key Dates

Recommendation

The filing reports significant insider selling by the CEO, even if executed under a pre-arranged 10b5-1 plan. While such plans are designed to avoid accusations of trading on material non-public information, large sales by a key executive can still be perceived negatively by the market. Without additional context on the company's performance, strategic outlook, or the executive's personal financial planning, a 'hold' recommendation is prudent. Investors should monitor future company announcements and broader market conditions for ORIC, as this transaction alone does not provide sufficient grounds for a 'buy' or 'sell' based on fundamental company value.

Keywords

Oric Pharmaceuticals, ORIC, Form 4, Insider Trading, Stock Sale, Jacob Chacko, CEO, Director, 10b5-1 Plan, Equity Transaction